Gerald I Shulman MD PhD, MACP, MACE, FRCP

Diabetes, Lipid Metabolism

George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular & Molecular Physiology; Investigator Emeritus, Howard Hughes Medical Institute, Co-Director, Yale Diabetes Research Center

Join to view full profile

789 Howard AveBldgNew Haven, CT 06519
Phone+1 203-737-1932
Fax+1 203-785-3588

Dr. Shulman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shulman's full profile Already have an account?

Summary

Dr. Gerald Shulman is a physician scientist and the George R. Cowgill Professor of Medicine and Cellular & Molecular Physiology at Yale School of Medicine and an Investigator Emeritus of the Howard Hughes Medical Institute. He received his medical degree from Wayne State University School of Medicine, and did his residency training in internal medicine at Duke University Medical Center and fellowship training in endocrinology/metabolism at the Mass General Hospital/Harvard Medical School. He has been in practice 38 years and specializes in diabetes and lipid metabolism.

Education & Training

Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1981 - 1986
Duke University HospitalResidency, Internal Medicine, 1979 - 1981
Wayne State University School of MedicineClass of 1979

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 1986 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Elected Member National Academy of Sciences, 2007
Elected Member Institute of Medicine, 2005
Elected Member The American Society for Clinical Investigation, 1990

Publications & Presentations

PubMed

A controlled-release mitochondrial protonophore attenuates early- and late-stage atheroprogression in mice.
Bernardo Gindri Dos Santos, Niki F Brisnovali, Connor Haney, Myles Coven, Homa Linda Sebzevari
Science Translational Medicine. 2026-07-15
3 citations
Distinct effects of ketogenic and non-ketogenic weight-loss diets on hepatic steatosis and mitochondrial metabolism in MASLD.
Sami F Qadri, Kimmo Porthan, Sylvie Dufour, Tiina E Lehtimäki, Kitt Falk Petersen
Journal of Hepatology. 2026-07-01
CIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severity.
Ikki Sakuma, Rafael C Gaspar, Henrique N Morgan, Jie Zheng, Ali R Nasiri
Cell Reports. 2026-06-23

Journal Articles

Metformin Inhibits Gluconeogenesis via a Redox-Dependent Mechanism in Vivo
Kitt F Petersen, Daniel F Vatner, Gerald I Shulman, Nature

Lectures

MR Imaging Glucose and Fat
ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/19/2018
An Extended-Release Mitochondrial Protonophore Reverses Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Diabetes
New Haven, CT - 6/13/2014
Argininosuccinate Synthetase Regulates Hepatic AMPK Activity Linking Protein Catabolism and Ureagenesis to Hepatic Glucose Metabolism
New Haven, CT - 6/15/2014

Press Mentions

Celebrating Physician-Scientist Mentorship and the Janeway SocietyJune 18th, 2026
Hsieh and Shulman Lauded for Their Work as MentorsJune 17th, 2026
To Fight Cancer, Try Adding ExerciseMay 14th, 2026

Grant Support

Targeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetesYALE UNIVERSITY2024–2028
Yale Center for Metabolic Phenotyping in Live Models of Obesity and DiabetesYALE UNIVERSITY2023–2028
Yale Diabetes Research CenterYALE UNIVERSITY1997–2028
Mechanism of Renal Cortical Insulin ResistanceYALE UNIVERSITY2022–2026
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human PrimatesYALE UNIVERSITY2019–2025